Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Announces Validation of US Patent

Premium

Santaris Pharma announced this week that the US Patent and Trademark Office has issued a inter partes re-examination certificate for a US patent held by the company and covering locked nucleic acids.

According to the company, the USPTO ruling upholds the claims within the patent, which had been the subject of re-examination proceedings initiated at the request of Isis Pharmaceuticals.

The patent in question, No. 6,770,748, is a continuation-in-part of another US patent that had also previously been the subject of an Isis re-examination request, according to Santaris.

"We are delighted that these lengthy procedures have been successfully concluded with USPTO confirming the patentability of our … patents,” Santaris President and CEO Henrik Stage said in a statement. “These are two of our fundamental patents, which provide broad protection for our … antisense drug platform based on the locked nucleic acid/bicyclic nucleic acid chemistries."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.